

SUPPLEMENTARY MATERIAL

Title: Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials

Sonja Ständer¹ · Gil Yosipovitch² · Eric L. Simpson³ · Brian S. Kim⁴ · Kenji Kabashima⁵ · Diamant Thaçi⁶ · Martin Metz⁷ · Zhen Chen⁸ · Sandra Hagen⁹ · Mike Bastian¹⁰

¹Department of Dermatology and Center for Chronic Pruritus, University Hospital Münster, Münster, Germany;

²Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery and Miami Itch Center, University of Miami, Miami, FL, USA; ³Department of Dermatology, Oregon Health & Science University, Portland, OR, USA; ⁴Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; ⁵Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan

⁶Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany;

⁷Institute of Allergology, Charité – Universitätsmedizin Berlin, Berlin, Germany; ⁸Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA; ⁹Regeneron GmbH, Munich, Germany; ¹⁰Sanofi, Frankfurt, Germany

Corresponding author: Mike Bastian

Email: Mike.Bastian@sanofi.com

Table S1 Baseline demographics and disease characteristics from patients analyzed from SOLO-
CONTINUE

	Dupilumab 300 mg qw (N = 69)	Dupilumab 300 mg q2w (N = 58)	Dupilumab 300 mg q4w (N = 61)	Dupilumab 300 mg q8w (N = 68)	Placebo (N = 68)
Demographic characteristics					
Age, years, descriptive					
Q1	29.0	27.0	26.0	27.5	27.5
Median	38	36	35	35	37
Q3	49.0	48.0	49.0	47.5	46.5
Race, n (%)					
White	48 (69.6)	45 (77.6)	46 (75.4)	47 (69.1)	45 (66.2)
Black or African American	3 (4.3)	3 (5.2)	1 (1.6)	6 (8.8)	6 (8.8)
Asian	12 (17.4)	10 (17.2)	12 (19.7)	14 (20.6)	13 (19.1)
Other	4 (5.8)	0	2 (3.3)	1 (1.5)	2 (2.9)
Not reported/missing	2 (2.9)	0	0	0	2 (2.9)
Sex, n (%)					
Male	35 (50.7)	26 (44.8)	27 (44.3)	39 (57.4)	42 (61.8)
Female	34 (49.3)	32 (55.2)	34 (55.7)	29 (42.6)	26 (38.2)
Disease characteristics					
Number n (%) of patients with duration of atopic dermatitis, years					
< 26 years	31 (44.9)	24 (41.4)	31 (50.8)	40 (58.8)	30 (44.1)
≥ 26 years	38 (55.1)	33 (56.9)	30 (49.2)	27 (39.7)	37 (54.4)
Missing	0	1 (1.7)	0	1 (1.5)	1 (1.5)
Number n (%) of patients with EASI-75 or with EDC IGA 0/1					
No	0	0	0	0	0
Yes	69 (100)	58 (100)	61 (100)	68 (100)	68 (100)
Number n (%) of patients with EDC IGA score					
IGA = 0	8 (11.6)	7 (12.1)	8 (13.1)	9 (13.2)	8 (11.8)
IGA = 1	42 (60.9)	39 (67.2)	43 (70.5)	44 (64.7)	45 (66.2)
IGA = 2	18 (26.1)	12 (20.7)	8 (13.1)	13 (19.1)	15 (22.1)
IGA = 3	1 (1.4)	0	2 (3.3)	2 (2.9)	0
IGA = 4	0	0	0	0	0
Number n (%) of patients with EASI-75					
No	0	3 (5.2)	1 (1.6)	1 (1.5)	2 (2.9)
Yes	69 (100)	55 (94.8)	60 (98.4)	67 (98.5)	66 (97.1)
EASI score, mean (SD)	2.5 (2.70)	2.3 (2.56)	2.4 (2.83)	2.2 (2.19)	2.2 (2.20)
Percent change in EASI from parent study	-91.9 (7.75)	-92.4 (8.65)	-92.6 (6.82)	-91.5 (8.01)	-92.2 (7.93)

baseline, mean (SD)					
Peak weekly average pruritus NRS, mean (SD)	1.9 (1.34)	1.9 (1.23)	1.9 (1.22)	1.8 (1.27)	2.0 (1.27)
BSA of atopic dermatitis, mean (SD)	7.6 (7.54)	6.7 (7.05)	8.5 (9.84)	8.1 (9.87)	7.1 (8.13)
SCORAD score, mean (SD)	15.2 (10.36)	15.0 (8.49)	15.8 (9.42)	15.8 (9.39)	14.5 (8.12)
POEM, mean (SD)	5.0 (4.82)	5.6 (4.78)	4.5 (3.86)	5.4 (4.66)	5.0 (4.94)
DLQI total score, mean (SD)	2.9 (4.65)	2.5 (2.45)	1.9 (2.49)	2.1 (2.33)	2.4 (2.82)
HADS total score, mean (SD)	5.5 (5.58) (n = 66)	6.1 (5.81) (n = 57)	5.8 (6.81) (n = 52)	5.9 (5.78) (n = 65)	5.2 (5.49) (n = 66)

BSA body surface area, DLQI Dermatology Life Quality Index, EASI Eczema Area and Severity

Index, EASI-75 75% improvement from baseline in EASI, EDC electronic data capture, IGA

Investigator's Global Assessment, HADS Hospital Anxiety and Depression Scale, NRS Numeric

Rating Scale, POEM Patient-Oriented Eczema Measure, Q quartile, q2w every 2 weeks, q4w every 4

weeks, q8w every 8 weeks, qw weekly, SCORAD SCORing Atopic Dermatitis, SD standard deviation